These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 2496742)
1. The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination. Bennett B; Booth NA; Croll A; Dawson AA Br J Haematol; 1989 Apr; 71(4):511-7. PubMed ID: 2496742 [TBL] [Abstract][Full Text] [Related]
2. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. Booth NA; Anderson JA; Bennett B J Clin Pathol; 1984 Jul; 37(7):772-7. PubMed ID: 6235248 [TBL] [Abstract][Full Text] [Related]
3. Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis: case report and literature review. Sane DC; Pizzo SV; Greenberg CS Am J Hematol; 1989 May; 31(1):53-7. PubMed ID: 2495717 [TBL] [Abstract][Full Text] [Related]
4. Bleeding in acute promyelocytic leukemia (APL): fibrinolysis or defibrination? Krsnik I; Escribá A; López-Rubio M; Alarcón C; del Potro E; Díaz-Mediavilla J Nouv Rev Fr Hematol (1978); 1991; 33(1):39-41. PubMed ID: 1945823 [TBL] [Abstract][Full Text] [Related]
5. Depressed plasma fibrinolytic activity in a group of patients with connective tissue diseases. Munkvad S; Gram J; Jespersen J Scand J Rheumatol; 1989; 18(5):277-82. PubMed ID: 2512638 [TBL] [Abstract][Full Text] [Related]
6. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes. Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392 [TBL] [Abstract][Full Text] [Related]
8. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator. Watahiki Y; Scully MF; Ellis V; Kakkar VV Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259 [TBL] [Abstract][Full Text] [Related]
9. Impairment of fibrinolysis during the growth of two murine mammary adenocarcinomas. Alonso DF; Farías EF; Bal de Kier Joffé E Cancer Lett; 1993 Jul; 70(3):181-7. PubMed ID: 8353814 [TBL] [Abstract][Full Text] [Related]
10. The coagulopathy in acute promyelocytic leukaemia--what have we learned in the past twenty years. Kwaan HC; Cull EH Best Pract Res Clin Haematol; 2014 Mar; 27(1):11-8. PubMed ID: 24907013 [TBL] [Abstract][Full Text] [Related]
11. Plasma urokinase-type plasminogen activator in patients with leukemias. Wada K; Takahashi H; Hanano M; Tatewaki W; Niwano H; Seki Y; Shibata A Leuk Lymphoma; 1994 Nov; 15(5-6):499-502. PubMed ID: 7874008 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of fibrinolytic capacity in plasma during thrombolytic therapy with single (scu-PA) or two-chain urokinase type plasminogen activator (tcu-PA) by a combined assay system for urokinase type plasminogen activator antigen and function. Wojta J; Binder BR; Huber K; Hoover RL Thromb Haemost; 1989 Apr; 61(2):289-93. PubMed ID: 2501899 [TBL] [Abstract][Full Text] [Related]
14. Annexin II cell surface and mRNA expression in human acute myeloid leukaemia cell lines. Olwill SA; McGlynn H; Gilmore WS; Alexander HD Thromb Res; 2005; 115(1-2):109-14. PubMed ID: 15567461 [TBL] [Abstract][Full Text] [Related]
15. [Structure, function and use of fibrinolysis-promoting and inhibiting factors]. Bachmann F Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901 [TBL] [Abstract][Full Text] [Related]
16. Fibrinolysis and coagulation in patients with infectious disease and sepsis. Philippé J; Offner F; Declerck PJ; Leroux-Roels G; Vogelaers D; Baele G; Collen D Thromb Haemost; 1991 Mar; 65(3):291-5. PubMed ID: 1904655 [TBL] [Abstract][Full Text] [Related]
17. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. Grøndahl-Hansen J; Agerlin N; Munkholm-Larsen P; Bach F; Nielsen LS; Dombernowsky P; Danø K J Lab Clin Med; 1988 Jan; 111(1):42-51. PubMed ID: 3121772 [TBL] [Abstract][Full Text] [Related]
18. Characteristics of fibrinolytic disorders in acute promyelocytic leukemia. Wang P; Zhang Y; Yang H; Hou W; Jin B; Hou J; Li H; Zhao H; Zhou J Hematology; 2018 Dec; 23(10):756-764. PubMed ID: 29724147 [TBL] [Abstract][Full Text] [Related]
19. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity. Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071 [TBL] [Abstract][Full Text] [Related]
20. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy]. Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]